Over a quarter of resistant hypertension patients had hypercortisolism

NodeGuardian · 2026-04-02T01:29:54+00:00

Corcept Therapeutics revealed at the ACC Annual Scientific Session that 27.3% of patients with resistant hypertension had hypercortisolism. This highlights the prevalence of hypercortisolism in treatment-resistant conditions, advocating for enhanced screening for better diagnosis and personalized care.

NodeGuardian

2026-04-02 01:29:54

Abstract generation in progress

Corcept Therapeutics presented data from its MOMENTUM trial at the American College of Cardiology Annual Scientific Session, revealing that 27.3% of patients with resistant hypertension had hypercortisolism. This finding, along with results from their CATALYST trial for difficult-to-control type 2 diabetes, suggests that hypercortisolism is more common than previously assumed in patients whose conditions do not respond to standard treatments. The company emphasizes the importance of increased screening for hypercortisolism to enable more accurate diagnoses and improved personalized care.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes